Chiara Tarantelli
Institute of Oncology Research(CH)Università della Svizzera italiana(CH)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Cutaneous lymphoproliferative disorders research, Monoclonal and Polyclonal Antibodies Research, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs(2015)282 cited
- → PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy(2017)117 cited
- → Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia(2019)82 cited
- → Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734(2020)70 cited
- → The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents(2019)69 cited
- → Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses(2019)69 cited
- → New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease(2018)68 cited
- → Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma(2014)62 cited
- → Daily intake ofLactobacillus caseiShirota increases natural killer cell activity in smokers(2011)61 cited
- → The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models(2019)43 cited